国际肿瘤学杂志››2015,Vol. 42››Issue (6): 442-444.doi:10.3760/cma.j.issn.1673-422X.2015.06.011
杨清梅,徐祖敏,官成浓
收稿日期:
2015-01-28出版日期:
2015-06-08发布日期:
2015-05-31通讯作者:
官成浓,Email:guanchengnong@163.com E-mail:guanchengnong@163.comYang Qingmei, Xu Zumin, Guan Chengnong
Received:
2015-01-28Online:
2015-06-08Published:
2015-05-31Contact:
Guan Chengnong E-mail:guanchengnong@163.com摘要:研究发现部分Trim蛋白家族成员与肿瘤发生发展过程相关。不同的Trim家族成员在肺癌、肝癌、结直肠癌、胃癌、乳腺癌等肿瘤中呈差异性表达,并通过调控p53活性、核转录因子-κB信号通路等影响肿瘤相关基因的表达,参与肿瘤进程。Trim家族成员可以作为抑癌基因或癌基因影响肿瘤细胞的增殖、分化、凋亡、侵袭迁移等生物学过程。
杨清梅,徐祖敏,官成浓. Trim蛋白家族与肿瘤[J]. 国际肿瘤学杂志, 2015, 42(6): 442-444.
Yang Qingmei, Xu Zumin, Guan Chengnong. Trim family and tumor[J]. Journal of International Oncology, 2015, 42(6): 442-444.
[1] Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment[J]. Nat Med, 2014, 20(11): 1242-1253. [2] Micale L, Chaignat E, Fusco C, et al. The tripartite motif: structure and function[J]. Adv Exp Med Biol, 2012, 770: 11-25. [3] Ozato K, Shin DM, Chang TH, et al. TRIM family proteins and their emerging roles in innate immunity[J]. Nat Rev Immunol, 2008, 8(11): 849-860. [4] Meroni G, DiezRoux G. TRIM/RBCC, a novel class of ′single protein RING finger′ E3 ubiquitin ligases[J]. Bioessays, 2005, 27(11): 1147-1157. [5] Khetchoumian K, Teletin M, Tisserand J, et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha[J]. Nat Genet, 2007, 39(12): 1500-1506. [6] Chambon M, Orsetti B, Berthe ML, et al. Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer[J]. Am J Pathol, 2011, 178(4): 1461-1469. [7] Tsai WW, Wang Z, Yiu TT, et al. TRIM24 links a noncanonical histone signature to breast cancer[J]. Nature, 2010, 468(7326): 927-932. [8] Kikuchi M, Okumura F, Tsukiyama T, et al. TRIM24 mediates liganddependent activation of androgen receptor and is repressed by a bromodomaincontaining protein, BRD7, in prostate cancer cells[J]. Biochim Biophys Acta, 2009, 1793(12): 1828-1836. [9] Ryu YS, Lee Y, Lee KW, et al. TRIM32 protein sensitizes cells to tumor necrosis factor (TNFα)induced apoptosis via its RING domaindependent E3 ligase activity against Xlinked inhibitor of apoptosis (XIAP)[J]. J Biol Chem, 2011, 286(29): 25729-25738. [10] Horn EJ, Albor A, Liu Y, et al. RING protein Trim32 associated with skin carcinogenesis has antiapoptotic and E3ubiquitin ligase properties[J]. Carcinogenesis, 2004, 25(2): 157-167. [11] Kano S, Miyajima N, Fukuda S, et al. Tripartite motif protein 32 facilitates cell growth and migration via degradation of Ablinteractor 2[J]. Cancer Res, 2008, 68(14): 5572-5580. [12] Liu J, Zhang C, Wang XL, et al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis[J]. Cell Death Differ, 2014, 21(11): 1792-1804. [13] Fitzgerald S, Sheehan KM, O′Grady A, et al. Relationship between epithelial and stromal TRIM28 expression predicts survival in colorectal cancer patients[J]. J Gastroenterol Hepatol, 2013, 28(6): 967-974. [14] Chen L, Chen DT, Kurtyka C, et al. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions[J]. J Biol Chem, 2012, 287(48): 40106-40118. [15] Chen L, MunozAntonia T, Cress WD. Trim28 contributes to EMT via regulation of Ecadherin and Ncadherin in lung cancer cell lines[J]. PloS One, 2014, 9(7): e101040. [16] Sho T, Tsukiyama, Sato t, et al. TRIM29 negatively regulates p53 via inhibition of Tip60[J]. Biochim Biophys Acta, 2014, 1813(6): 1245-1253. [17] Sun H, Dai X, Han B. TRIM29 as a novel biomarker in pancreatic adebocarnoma[J]. Dis Markers, 2014, 2014: 317817. [18] Zhou ZY, Yang GY, Zhou J, et al. Significance of TRIM29 and β-catenin expression in nonsmallcell lung cancer[J]. J Chin Med Assoc, 2012, 75(6): 269-274. [19] Hawthorn L, Stein L, Panzarella J, et al. Characterization of celltype specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung[J]. Lung Cancer, 2006, 53(2): 129-142. [20] Fristrup N, BirkenkampDemtroder K, Reinert T, et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in nonmuscleinvasive bladder cancer[J]. Am J Pathol, 2013, 182(2): 339-349 . [21] Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy[J]. Int J Cancer, 2004, 112(1): 14-25. [22] Katkoori VR, Shanmugam C, Jia X, et al. Prognostic significance and gene expression profiles of p53 mutations in microsatellitestable stage Ⅲ colorectal adenocarcinomas[J]. PLoS One, 2012, 7(1): e30020. [23] Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells[J]. Blood, 2002, 99(5): 1745-1757. [24] Kosaka Y, Inoue H, Ohmachi T, et al. Tripartite motifcontaining 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer[J]. Ann Surg Oncol, 2007, 14(9): 2543-2549. [25] Horio M, Kato T, Mii S, et al. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer[J]. Cancer Med, 2012, 1(2):218-229. [26] Iwakoshi A, Murakumo Y, Kato T, et al. RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations[J]. Pathol Int, 2012, 62(5): 324-330. [27] Tsukamoto H, Kato T, Enomoto A, et al. Expression of Ret finger protein correlates with outcomes in endometrial cancer[J]. Cancer Sci, 2009, 100(10): 1895-1901. [28] Tomar D, Sripada L, Prajapati P, et al. Nucleocytoplasmic trafficking of TRIM8, a novel oncogene, is involved in positive regulation of TNF induced NFκB pathway[J]. PLoS One, 2012, 7(11): e48662. [29] Caratozzolo MF, Valletti A, Gigante M, et al. TRIM8 antiproliferative action against chemoresistant renal cell carcinoma[J]. Oncotarget, 2014, 5(17): 7446-7457. |
[1] | 刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325. |
[2] | 杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337. |
[3] | 袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343. |
[4] | 陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349. |
[5] | 郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353. |
[6] | 张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358. |
[7] | 许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363. |
[8] | 王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369. |
[9] | 张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375. |
[10] | 高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381. |
[11] | 王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384. |
[12] | 刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273. |
[13] | 杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279. |
[14] | 王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285. |
[15] | 张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||